Table 1. Relationship between LAPTM4B genotypes and clinicopathological features of HCC.
Variables | Patients | LAPTM4B genetype | Pa | ||
*1/1 | *1/2 | *2/2 | |||
Gender | 0.172 | ||||
Male | 57 | 16 | 32 | 9 | |
Female | 11 | 6 | 3 | 2 | |
Age (years) | 0.415 | ||||
<65 | 44 | 14 | 21 | 9 | |
≥65 | 24 | 8 | 14 | 2 | |
Viral status | 0.171 | ||||
Hepatitis virus B | 49 | 16 | 22 | 11 | |
Hepatitis virus C | 12 | 3 | 9 | 0 | |
Both hepatitis virus B and C | 2 | 0 | 2 | 0 | |
Non-B, Non-C | 5 | 3 | 2 | 0 | |
Tumor size | 0.852 | ||||
<5 cm | 37 | 13 | 18 | 6 | |
≥5 cm | 31 | 9 | 17 | 5 | |
portal vein invasion | 0.001 | ||||
No | 49 | 22 | 22 | 5 | |
Yes | 19 | 0 | 13 | 6 | |
Histopathological differentiation | 0.009 | ||||
WD | 20 | 12 | 6 | 2 | |
MD | 25 | 8 | 14 | 3 | |
PD | 23 | 2 | 15 | 6 | |
Serum AFP level | 0.144 | ||||
<25 ng/ml | 35 | 14 | 18 | 3 | |
≥25 ng/ml | 33 | 8 | 17 | 8 | |
TNM stage | <0.001 | ||||
I–II | 23 | 18 | 4 | 1 | |
III–IV | 45 | 4 | 31 | 10 | |
Recurrence | <0.001 | ||||
No | 17 | 12 | 5 | 0 | |
Yes | 51 | 10 | 30 | 11 |
LAPTM4B, Lysosomal protein transmembrane 4 beta; HCC, hepatocellular carcinoma; a, Chi-square test.